Knowledge, Attitudes, and Practices of Physicians Regarding Targeted Drug Therapy for Lung Cancer
DOI: https://doi.org/10.2147/ijgm.s465079
IF: 2.145
2024-06-11
International Journal of General Medicine
Abstract:Di Nie, 1, 2, &ast Haozhi Ma, 1, 2, &ast Guosheng Huang, 1 Tianzeng Zhao, 1 Wenxian Li 1 1 Thoracic Surgery Department, The First Affiliated Hospital of Nanyang Medical College, Nanyang, People's Republic of China; 2 Graduate Division Department, Xinxiang Medical University, Xinxiang, Chian &astThese authors contributed equally to this work Correspondence: Wenxian Li, Thoracic Surgery Department, The First Affiliated Hospital of Nanyang Medical College, Nanyang, People's Republic of China, Tel +86-15565269994, Email Purpose: This study aimed to examine the KAP of physicians regarding targeted drug therapy for lung cancer in China. Methods: This cross-sectional study enrolled physicians working in hospitals in Nanyang. A self-administered questionnaire was developed (Cronbach's α=0.912) to collect the demographic information and KAP. Results: This study included 191 valid questionnaires. Most participants were male (70.2%) and aged 36– 50 (55.5%). The median knowledge score was 29 (24– 31) (/36, 80.6%), the mean attitude score was 42 (39– 44) (/50, 84.0%), and the mean practice score was 28 (26– 29) (/30, 93.3%), indicating sufficient knowledge, positive attitudes, and proactive practice. The female gender (OR=5.291, 95% CI: 1.426– 19.634, P=0.013), working in non-public tertiary hospitals (OR=0.053, 95% CI: 0.008– 0.360, P=0.003), and working in medical oncology (OR=10.764, 95% CI: 2.638– 43.922, P=0.001) were independently associated with adequate knowledge. Only the knowledge scores (OR=1.121, 95% CI: 1.036– 1.212, P=0.004) were independently associated with a positive attitude. Only the attitude scores (OR=1.895, 95% CI: 1.333– 2.694, P< 0.001) were independently associated with proactive practice. Conclusion: Physicians working in thoracic surgery, respiratory medicine, or medical oncology displayed sufficient knowledge, positive attitude, and proactive practice toward targeted therapy for lung cancer. Keywords: knowledge, attitude, practice, lung cancer, targeted therapy, physician Lung cancer is the most common cancer worldwide, with an estimated 2,480,301 new cases in 2022 (12.4% of all cancers), and with the highest contribution to cancer-related mortality, with 1,817,172 deaths (18.7% of all cancer-related deaths). 1 Lung cancer is an umbrella term that encompasses several types of disease with different biology (mainly non-small cell lung cancer (NSCLC), with 85–90% of cases, and small cell lung cancer (SCLC)), and patients with the same cancer subtype display different tumor biology due to the presence of various driver mutations (eg, EGFR, ALK, PI3K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS1) in the tumor. 2–4 Fortunately, in the era of precision medicine, several of those mutated genes are actionable and can be targeted with drugs against EGFR (erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib), ALK (crizotinib, ceritinib, alectinib, brigatinib, ensartinib, and lorlatinib), RET (selparcatinib and pralsetinib), MET (capmatinib and repotinib), BRAF (dabrafenib and trametinib), NTRK (larotrectinib and entrectinib), and ROS1 (crizotinib, ceritinib, lorlatinib, and entrectinib). 2–4 Despite the efficacy of such drugs, in 33 states in the United States of America (USA), only 66% of the patients with EGFR- or ALK-mutated lung cancer in 2020–2021 received a targeted therapy. 5 Immunotherapy is also a novel type of targeted therapy that specifically inhibits the tumor's immune escape (ie, the ability of a tumor to induce immune tolerance toward cancer cells). 3,4 The 5-year survival of patients with NSCLC is 19%, while the 5-year survival of patients with SCLC is 6.3%. 6,7 Still, appropriate knowledge of these drugs is necessary for their correct use or to consider referring a patient to a specialist who will provide targeted therapy. The prescription of targeted therapy is based on the indications, the mutations, resistance development, and prognosis. 8 Knowledge, attitude, and practice (KAP) is a structured survey method used to investigate the gaps, misunderstandings, and misconceptions toward a specific subject that can constitute barriers to the correct application of the subject in a specific population. 9,10 Very little data are available in the literature regarding the KAP toward targeted therapies among specialists. Even for traditional chemotherapy, very few studies examined the oncologists' KAP toward specific subjects such as resistance. 11–13 Previous studies revealed variable KAP toward lung cancer biomarker testing among pulmonologists in the United States of Ameri -Abstract Truncated-
medicine, general & internal